After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.
TL;DR
- Compass Pathways CEO Kabir Nath left a senior role in traditional pharmaceuticals to lead a startup developing a psilocybin pill (COMP360) for treatment-resistant depression.
- The company is preparing for a potential FDA approval, which could come as soon as next year, and has significantly expanded its operations and workforce.
- Failure to gain FDA approval could lead to bankruptcy for Compass Pathways, impacting patients with limited treatment options.
- Psilocybin's medical research history has been complex, with periods of prohibition followed by renewed scientific interest, particularly since 2000.
- Compass Pathways' treatment protocol involves administering the psilocybin pill in a controlled clinical setting for approximately six hours, followed by the patient going home.
- Recent trial results show nearly half of participants experienced a significant reduction in depressive symptoms within six weeks of treatment.
- Other psychedelic drug companies, like AtaiBeckley, are also developing treatments, but Compass Pathways appears to be further along in the FDA approval process.
- The company is actively engaging with healthcare providers to prepare for the potential launch and administration of the drug in clinical settings.